| Bioactivity | Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity[1][2]. | ||||||||||||
| Invitro | Meisoindigo (Dian III; 5-20 μM; for 24 hours) inhibits growth of the AML cell lines[1]. Meisoindigo (10 μM; for 24 hours) induces apoptosis of acute myeloid leukemia[1]. Meisoindigo (5-10 μM; for 24 hours) causes cell-cycle arrest[1]. Meisoindigo (5-10 μM; for 24 hours) increases the cleaved caspase-3 and pro-apoptotic Bak, and decreases Bcl-2 and Bcl-xL levels in HL-60 cells[1]. Meisoindigo (10, 30, 50, 100, 150 μM; 24 hours) interdicts LPS-induced (1 μg/mL) NLRP3 inflammasome activation and M1/M2 polarization through down-regulation of TLR4 pathways after OGD/R in HT-22 and BV2 cells[2]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | Meisoindigo | ||||||||||||
| CAS | 97207-47-1 | ||||||||||||
| Formula | C17H12N2O2 | ||||||||||||
| Molar Mass | 276.29 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|